STUDY OBJECTIVES: To determine predictors of neuropsychological functioning in patients with obstructive sleep apnea (OSA) and whether treatment with 2-week continuous positive airway pressure (CPAP) or supplemental oxygen would improve cognitive functioning. DESIGN: Randomized placebo-controlled design. SETTING: University-based clinical research center. PATIENTS: Forty-six patients with untreated OSA. INTERVENTIONS: Two-week CPAP, supplemental oxygen, or placebo-CPAP. MEASUREMENTS AND RESULTS: Participants underwent polysomnography and completed a neuropsychological test battery before and after treatment. Prior to treatment, patients with OSA showed diffuse impairments, particularly in terms of speed of information processing, attention and working memory, executive functioning, learning and memory, as well as alertness and sustained attention. A global deficit score at baseline was positively correlated with percentage of stage 1 sleep (p = .049) only and was not correlated with obesity, daytime sleepiness, depression, fatigue, OSA severity, and the other polysomnography variables. The 3 treatment groups (therapeutic-CPAP, supplemental oxygen, and placebo-CPAP) were compared using repeated-measures analysis of variance (ANOVA). There was no significant Time x Treatment interaction for the global deficit score. When examining individual neuropsychological test scores, two thirds of them improved with time regardless of treatment, although only Digit Vigilance-Time (p = .020) showed significant improvement specific to CPAP treatment. CONCLUSION: The present results suggest that Digit Vigilance-Time might be the most sensitive neuropsychological test for measuring the effects of the treatments. In general, 2 weeks of CPAP or oxygen-supplementation treatment was insufficient to show overall beneficial cognitive effects, as compared with placebo-CPAP. However, 2 weeks of CPAP treatment might be helpful in terms of speed of information processing, vigilance, or sustained attention and alertness.
RCT Entities:
STUDY OBJECTIVES: To determine predictors of neuropsychological functioning in patients with obstructive sleep apnea (OSA) and whether treatment with 2-week continuous positive airway pressure (CPAP) or supplemental oxygen would improve cognitive functioning. DESIGN: Randomized placebo-controlled design. SETTING: University-based clinical research center. PATIENTS: Forty-six patients with untreated OSA. INTERVENTIONS: Two-week CPAP, supplemental oxygen, or placebo-CPAP. MEASUREMENTS AND RESULTS:Participants underwent polysomnography and completed a neuropsychological test battery before and after treatment. Prior to treatment, patients with OSA showed diffuse impairments, particularly in terms of speed of information processing, attention and working memory, executive functioning, learning and memory, as well as alertness and sustained attention. A global deficit score at baseline was positively correlated with percentage of stage 1 sleep (p = .049) only and was not correlated with obesity, daytime sleepiness, depression, fatigue, OSA severity, and the other polysomnography variables. The 3 treatment groups (therapeutic-CPAP, supplemental oxygen, and placebo-CPAP) were compared using repeated-measures analysis of variance (ANOVA). There was no significant Time x Treatment interaction for the global deficit score. When examining individual neuropsychological test scores, two thirds of them improved with time regardless of treatment, although only Digit Vigilance-Time (p = .020) showed significant improvement specific to CPAP treatment. CONCLUSION: The present results suggest that Digit Vigilance-Time might be the most sensitive neuropsychological test for measuring the effects of the treatments. In general, 2 weeks of CPAP or oxygen-supplementation treatment was insufficient to show overall beneficial cognitive effects, as compared with placebo-CPAP. However, 2 weeks of CPAP treatment might be helpful in terms of speed of information processing, vigilance, or sustained attention and alertness.
Authors: S Kotterba; K Rasche; W Widdig; C Duscha; S Blombach; G Schultze-Werninghaus; J P Malin Journal: J Neurol Sci Date: 1998-07-15 Impact factor: 3.181
Authors: In-Soo Lee; Wayne A Bardwell; Rujvi Kamat; Lianne Tomfohr; Robert K Heaton; Sonia Ancoli-Israel; Jose S Loredo; Joel E Dimsdale Journal: Drug Discov Today Dis Models Date: 2011
Authors: Vincenza Castronovo; Paola Scifo; Antonella Castellano; Mark S Aloia; Antonella Iadanza; Sara Marelli; Stefano F Cappa; Luigi Ferini Strambi; Andrea Falini Journal: Sleep Date: 2014-09-01 Impact factor: 5.849
Authors: Lucas M Donovan; Peter J Rise; Shannon S Carson; Laura C Feemster; Matthew F Griffith; Vishesh K Kapur; Jerry A Krishnan; Peter K Lindenauer; Richard A Mularski; Edward T Naureckas; Brian N Palen; Elizabeth C Parsons; Laura J Spece; Michael V Vitiello; David H Au Journal: Ann Am Thorac Soc Date: 2017-12
Authors: Daniel Norman; Wayne A Bardwell; Jose S Loredo; Sonia Ancoli-Israel; Robert K Heaton; Joel E Dimsdale Journal: Sleep Breath Date: 2008-08 Impact factor: 2.816
Authors: Clete A Kushida; Deborah A Nichols; Tyson H Holmes; Stuart F Quan; James K Walsh; Daniel J Gottlieb; Richard D Simon; Christian Guilleminault; David P White; James L Goodwin; Paula K Schweitzer; Eileen B Leary; Pamela R Hyde; Max Hirshkowitz; Sylvan Green; Linda K McEvoy; Cynthia Chan; Alan Gevins; Gary G Kay; Daniel A Bloch; Tami Crabtree; William C Dement Journal: Sleep Date: 2012-12-01 Impact factor: 5.849